EMBRACE: Motor milestone results

Interim results: SPINRAZA® improves achievement of motor milestones1

  • The study was terminated early after a median follow-up of 302 days1
  • At the end of the study, all SPINRAZA®-treated patients were alive and no patient in either group required the use of permanent ventilation1
  • More SPINRAZA®-treated patients met the pre-specified motor milestone responder criteria compared with sham-control patients*1

HINE-2 motor milestone responders*1

*A motor milestone responder was defined according to the Hammersmith Infant Neurological Examination (HINE) Section 2: ≥2 point increase (or maximal score) in ability to kick, or ≥1-point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking, and improvement in more categories of motor milestones than worsening.1

age 9*
Later-onset (Type III) SMA
treated with SPINRAZA®
~5.5 years as of 9/18

*Age at time of photo shoot.

1. SPINRAZA® Summary of Product Characteristics.